P182 Real-world persistence and treatment patterns in psoriatic arthritis patients treated with anti-IL17 therapy: the PERFIL-17 study

Abstract Background/Aims Interleukin-17 inhibitors (anti-IL-17) have provided an additional treatment option in psoriatic arthritis (PsA). This study aims to describe the patient profile, patterns and persistence PsA patients treated with ixekizumab secukinumab a real-life setting. Methods A multicentre, retrospective was conducted at 8 Spanish hospitals. Three cohorts of adult patients, newly initiating anti-IL-17A (secukinumab 150mg [SECU150], 300mg [SECU300], [IXE]), between January 2019 March 2020 were included. Data exposed anti-IL-17 drugs follow-up visit collected until 2021. Demographic clinical characteristics, patterns, analysed descriptively. Continuous data presented as mean (standard deviation [SD]) categorical variables frequencies percentage. Persistence rates 3/6/12 months calculated. Results total 221 (SECU150: 103 [46.6%], SECU300: 38 [17.2%] IXE: 80 [36.2%]). Treatment differed by characteristics: SECU150 more moderate less peripheral joint damage, while SECU300 included higher rate enthesitis active psoriasis. IXE showed longer time since diagnosis, frequent co-morbidities, damage psoriasis diagnosed. 77.8% previously csDMARDs monotherapy 72.9% bDMARDs/tsDMARDs (93.8% IXE, 68.4% 58.3% SECU150). Mean number previous bDMARDS/tsDMARDS 2.4 (1.5), 1.7 (0.9) 1.6 (1.0), respectively. Overall, treatments found 97.2%, 88.4% 81.0% 3, 6 12 months, respectively, being 83.1% for SECU150, 64.5% 86.4% one year. The most reason discontinuation lack effectiveness (13.8%). Conclusion Most Spain had severe disease, high skin involvement received least 1 bDMARD/tsDMARD. More than 80% year persistent treatments, observing highest followed SECU300. Disclosure B. Ibañez: Consultancies; B.J.I. has consulting fees from UCB, AMGEN, JANSSEN. Honoraria; honoraria ABBVIE, LILLY, JANSSEN, NOVARTIS. Other; support attending meetings and/or travel NOVARTIS, UCB. C. Manteca: C.F.M. Inscripcion on line Congreso SER, EULAR. E. Rubio: None. Raya: A. Pérez-Linaza: R. Hernandez: R.H. Lilly, Novartis, Janssen, Pfizer, Abbie. Grants/research support; present manuscript Lilly. fee expert testimony participation Safety Monitoring Board or Advisory Novartis. S. Manrique-Arija: M. Núñez: Shareholder/stock ownership; M.N. is employee minor shareholder Diaz: S.D. L. Trancho: L.T. García de Vicuña: R.G.D.V. Abbvie, Biogen, MSD. Sandoz. funding research MSD, Kiprianos (Non-author Presenter): A.P. Eli Lilly Company.